Skip to main content
Caplight Logo









QurCan Therapeutics

QurCan Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.qurcan.com/

Last Round

Accelerator

Oct 5, 2022

Total Funding Raised

$6.15M

Company Overview

QurCan Therapeutics is a biotechnology company that develops a proprietary nanoparticle drug delivery platform for targeted therapeutics to treat cancer and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Advanced Materials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

drug delivery platformnanoparticle drug deliverymRNA deliveryblood-brain barrier deliverygene deliveryLNP deliverysiRNA deliveryCNS drug deliveryextrahepatic deliverycancer therapeuticsbiotech licensingnanomedicinepolymer-lipid nanoparticlehypoxic tumors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

QurCan Therapeutics Comparables

Compare QurCan Therapeutics with similar companies based on industry and business-model similarity.

QurCan Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nanite, Inc.
86%
CereCura Nanotherapeutics
84%
Nosis Bio
79%

QurCan Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorOct 5, 2022
GrantSep 1, 2022
SeedMay 17, 2021
SeedJan 28, 2020
SeedApr 8, 2019
Grant
Mar 21, 2019

Key People

Founding team and executive leadership

Mohammad Ali Amini

President & CEO

Executive Team

QurCan Therapeutics Investors

Notable investors and investment history

QurCan Therapeutics investors
InvestorRounds
Ontario Brain InstituteGrant, Seed
MEDTEQ+Seed
Mission BioCapitalAccelerator
National Research Council of CanadaGrant
PfizerAccelerator
FACITSeed
Ontario Centre of InnovationSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2022

    $76K grant received from National Research Council of Canada.

  • May 17, 2021

    $3M round led by FACIT

QurCan Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

QurCan Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about QurCan Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range9
Year Founded2018
Last FundingOct 5, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?